

Paxlovid Drug interactions

| Medication class | Drugs within the class that are contraindicated with nirmatrelvir/ritonavir due to increased risk of toxicity |
|--|---|
| Discontinuing these medications is not feasible due to long half-life or treatment indication and specificity of pharmacologic effect. Use of an alternative COVID-19 therapeutic agent is recommended. | |
| Antianginals | Ranolazine |
| Antiarrhythmics | Amiodarone, dronedarone, flecainide, propafenone, quinidine |
| Anti-cancer agents | Neratinib, venetoclax |
| Antipsychotics | Lurasidone, pimozide, clozapine |
| Endothelin receptor antagonists | Bosentan |
| Analgesic (narcotic) | Fentanyl |
| PDE5 inhibitors for treatment of pulmonary arterial hypertension | Sildenafil, tadalafil, vardenafil |
| Only start nirmatrelvir/ritonavir if the interacting drug can be safely held/replaced. Consultation with the patient's specialist provider or pharmacist may be warranted. | |
| α_1 adrenergic receptor antagonists | Alfuzosin |
| Anticoagulants, antiplatelets | Rivaroxaban, ticagrelor |
| Anti-gout agents | Colchicine |
| Beta-adrenoreceptor agonist, long-acting | Salmeterol |
| Ergot derivatives | Dihydroergotamine, ergonovine, ergotamine, methylergonovine |
| GI motility agents | Cisapride |
| Lipid-modifying agents | Lomitapide, lovastatin, simvastatin |
| PDE5 inhibitor for erectile dysfunction | Vardenafil |
| Sedatives/hypnotics | Triazolam, midazolam (oral) |

| Medication class | Drugs within the class that are contraindicated with nirmatrelvir/ritonavir due to potential loss of nirmatrelvir/ritonavir efficacy |
|--------------------|--|
| Anti-cancer agents | Apalutamide, enzalutamide |
| Anticonvulsants | Carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone |
| Antimycobacterials | Rifampin, rifapentine |
| Natural products | St. John's Wort (<i>Hypericum perforatum</i>) |